Скачать или смотреть How Monoclonal Antibodies Protect Infants from RSV: A Breakthrough in Prevention

Respiratory Syncytial Virus (RSV) can be severe, especially in infants under six months. Discover how long-acting monoclonal antibodies like nirsevimab are revolutionizing RSV prevention, reducing hospitalizations by up to 79%. Learn about the effectiveness, protection duration, and why this is a game-changer for newborn health. Stay informed about the latest advancements in pediatric healthcare and protect your little ones during the RSV season.
Key Topics Covered:
What is RSV and why is it dangerous for infants?
How do monoclonal antibodies work to prevent RSV?
Real-world effectiveness of nirsevimab in European studies
Protection duration and what parents need to know
The role of immunization in reducing RSV-related hospitalizations
RSVPrevention #MonoclonalAntibodies #InfantHealth #PediatricCare #NewbornProtection